Top

Cancer Causes & Control

Published in:

01-04-2008 | Original Paper

Dietary phytoestrogen intake—lignans and isoflavones—and breast cancer risk (Canada)

Authors: Michelle Cotterchio, Beatrice A. Boucher, Nancy Kreiger, Catherine A. Mills, Lilian U. Thompson

Published in: Cancer Causes & Control | Issue 3/2008

Abstract

Objective

To evaluate whether phytoestrogen intake is associated with reduced breast cancer risk, using a novel phytoestrogen database.

Methods

Population-based breast cancer cases aged 25–74 years (diagnosed 2002–2003) were identified using Ontario Cancer Registry (n = 3,063) and controls (n = 3,430) were an age-stratified random sample of women identified through random digit dialing. An epidemiologic and Block food frequency questionnaire—expanded to include phytoestrogen-containing foods—was mailed to all subjects. The recently published Ontario phytoestrogen database was applied to FFQ responses to estimate intake. Multivariate logistic regression provided odds ratio (OR) estimates, while controlling for confounders.

Results

Among all women, lignan intake was associated with a reduced breast cancer risk (Q5 vs. Q1 MVOR: 0.81, 95% CI: 0.65, 0.99); however, following stratification by BMI, this reduction in risk was statistically significant only among overweight (BMI > 25) women. Total phytoestrogen intake was also associated with a risk reduction among overweight women only. Among pre-menopausal women, total phytoestrogen intake was associated with a significant reduction in breast cancer risk among overweight women only (Q5 vs. Q1 MVOR: 0.51, 95% CI: 0.30, 0.87). Among post-menopausal women, no statistically significant association was observed between breast cancer risk and isoflavones or lignans.

Conclusion

Lignan intake may be associated with reduced breast cancer risk among pre-menopausal women, and our data suggest BMI modifies this association.

Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N (2006) Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans and coumestan. Nutr Cancer 54:184–201PubMed

Horn-Ross P, Lee M, John EM, Koo J (2000) Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control 11:299–302PubMed

Milder I, Feskens E, Arts I, de Mesquita H, Hollman P, Kromhout D (2005) Intake of the plant lignans Secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr 135:1202–1207PubMed

Gallo D, Giacomelli S, Cantelmo F et al (2001) Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 69:153–164PubMed

Kim H, Hall P, Smith M, Kirk M, Prasain J, Barnes S, Grubbs C (2004) Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J Nutr 134(supp12):3445S–3452SPubMed

Chen J, Thompson L (2003) Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res Treat 80:163–170PubMed

Thompson L, Seidl M, Rickard S, Orcheson L, Fong H (1996) Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26:159–165PubMed

Saarinen N, Huovinen R, Warri A, Makela S et al (2002) Enterolactone inhibits the growth of 7,12-dimethylbenzanthrene-induced mammary carcinomas in the rat. Mol Cancer Ther 1:869–876PubMed

Wang L, Chen J, Thomson Lu (2005) The inhibitory effect of flazseed on the growth and metastasis of estrogen receptor negative human breast cancer xenografts is attributed to both its lignan and oil components. Int J Cancer 116:793–798PubMed

10.

Power K, Saarinen N, Chen J, Thompson L (2006) Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein do not promote the growth of MCF-7 xenografts in ovariectomized athymic mice. Int J Cancer 118:1316–1320PubMed

11.

Ju Y, Allred K, Allred C, Helferich W (2006) Genistein stimulates growth of human breast cancer cells in a novel postmenopausal animal model with low plasma estradiol concentrations. Carcinogenesis 27:1292–1299PubMed

12.

Jungestrom M, Thompson L, Dabrosin C (2007) Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 13:1061–1067

13.

Parkin D, Whelan S, Ferley J, Raymond L, Young J (1997) Cancer incidence in five continents. International Agency for Research on Cancer (IARC), Lyon, France

14.

De Kleijn M, van der Schouw Y, Wilson P, Adlercreutz H, Mazur W, Grobbee D, Jacques P (2001) Intake of dietary phytoestrogens is low in postmenopausal women in the United States: The Framingham Study. J Nutr 131:1826–1832PubMed

15.

Ingram D, Sanders K, Kolybaba M, Lopez D (1997) Case–control study of phyto-oestrogens and breast cancer. Lancet 350:990–994PubMed

16.

Zheng W, Dai Q, Custer L, Shu X, Wen WQ, Jin F, Franke A (1999) Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 8:35–40PubMed

17.

Hirose K, Tajima K, Hamajima N, Inoue M, Takezaki T, Kuroishi T, Yoshida M, Tokudome S (1995) A large-scale, hospital-based case–control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 86:146–154PubMed

18.

Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H (2001) Serum enterolactone and risk of breast cancer: a case–control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 10:339–344PubMed

19.

McCann S, Moysich K, Freudenheim J, Ambrosone CB, Shields PG (2002) The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 132:3036–3041PubMed

20.

McCann S, Muti P, Vito D, Edge S, Trevisan M, Freudenheim J (2004) Dietary lignan intakes and risk of pre- and post-menopausal breast cancer. Int J Cancer 111:440–443PubMed

21.

Wu A, Ziegler R, Horn-Ross P, Nomura A, West D, Kolonel L, Rosenthal J, Hoover R, Pike M (1996) Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 5:901–906PubMed

22.

Wu A, Wan P, Hankin J, Tseng C, Yu M et al (2002) Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491–1496PubMed

23.

Dai Q, Shu X, Jin F, Potter J, Kushi L et al (2001) Population-based case–control study of soyfood intake and breast cancer risk in Shanghi. Br J Cancer 85:372–378PubMed

24.

Dai Q, Franke A, Jin F, Shu X, Hebert J, Custer L, Cheng J, Gao Y, Shang W (2002) Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 11:815–821PubMed

25.

Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S (2003) Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906–913PubMed

26.

Linseisen J, Piller R, Hermann S, Chang-Claude J (2004) Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case–control study. Int J Cancer 110:284–290PubMed

27.

Piller R, Chang-Claude J, Linseisen J (2006) Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev 15:225–232PubMed

28.

Fink B, Steck S, Wolff M, Britton J, Kabat G, Schroeder J, Teitelbaum S, Neugut A, Gammon M (2006) Dietary flavonoid intake and breast cancer risk among women on Long Island. Am J Epidemiol 165:514–523PubMed

29.

Touillaud M, Thiebaut A, Niravong M, Boutron-Ruault M.-C., Clavel-Chapelon F (2006) No association between dietary phytoestrogens and risk of premenopausal breast cancer risk in a French cohort study. Cancer Epidemiol Biomarkers Prev 15:2574–2576PubMed

30.

Verheus M, vanGils C, Keinan-Boker L, Grace P, Binghan S, Peeters P (2007) Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 25:648–655PubMed

31.

Touillaud M, Thiebaut A, Fournier A, Niravong M, Boutron-Ruault M, Clavel-Chapelon F (2007) Lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 99:475–486PubMed

32.

Horn-Ross P, John E, Lee M, Stewart S, Koo J, Sakoda L, Shiau A, Goldstein J, Davis P, Perez-Stable E (2001) Phytoestrogen consumption and breast cancer risk in a multiethnic population. Am J Epidemiol 154:434–441PubMed

33.

Horn-Ross P, Hoggart K, West D, Krone M, Stewart S et al (2002) Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 13:407–415PubMed

34.

Keinan-Boker L, van Der Schouw Y, Grobbee D, Peeters P (2004) Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 79:282–288PubMed

35.

den Tonkelaar I, Keinan-Boker L, Vant Veer P, Arts C, Adlercreutz H, Thijssen J, Peeters P (2001) Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:223–228

36.

Yuan J, Wang Q, Ross R, Henderson B, Yu M (1995) Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 71:1353–1358PubMed

37.

Key T, Sharp G, Appleby P, Beral V, Goodman M, Soda M, Mabuchi K (1999) Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 81:1248–1256PubMed

38.

Grace P, Taylor J, Low Y, Luben R, Mulligan A, Botting N, Dowsett M, Welch A, Khaw K, Wareham N, Day N, Bingham S (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and nutrition-Norfolk. Cancer Epidemiol Biomarks Prev 13:698–708

39.

Zeleniuch-Jacquotte A, Aldercreutz H, Shore R, Koenig K, Kato I, Arslan A, Toniolo P (2004) Circulating enterolactone and risk of breast cancer: a prospective study in New York. Br J Cancer 9:99–105

40.

Messina M, Nagata C, Wu A (2006) Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55:1–12PubMed

41.

Mulligan A, Welch A, McTaggart A, Bhaniani A, Bingham S (2007) Intakes and sources of soya foods and isoflavones in a UK population cohort (EPIC-Norfolk). Eur J Clin Nutr 61:248–254PubMed

42.

Trock B, Hilakivi-Clarke L, Clarke R (2006) Meta-analysis of soy intake and breast cancer risk. JNCI 98:459–471PubMed

43.

Reinli K, Block G (1996) Phytoestrogen content of foods—a compendium of literature values (review). Nutr Cancer 26:123–148PubMed

44.

USDA. US Department of Agriculture, Agricultural Research Service (2007) USDA-Iowa State University Database on the Isoflavone Content of Foods, Release 1.4 - 2007. Nutrient Data Laboratory Web site: http://www.ars.usda.gov/nutrientdata

45.

Mazur W, Duke J, Wahala K, Rasku S, Adlercreutz H (1998) Isoflavonoids and lignans in legumes: nutritional and health aspects on humans. J Nutr Biochem 9:193–200

46.

Liggins J, Bluck L, Runswick S, Atkinson C, Coward WA et al (2000) Daidzein and genistein content of vegetables. Br J Nutr 84:717–725PubMed

47.

Liggins J, Bluck L, Runswick S, Atkinson C, Coward W, Bingham S (2000) Daidzein and genistein content of fruits and nuts. J Nutr Biochem 11:326–331PubMed

48.

Mazur W, Adlercreutz H (2000) Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 16:654–658PubMed

49.

Milder I, Arts I, van de Putte B, Venema D, Hollman P (2005) Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 93:393–402PubMed

50.

Nurmi T, Heinonen S, Mazur W, Deyama T, Nishibe S, Aldercreutz H (2003) Lignans in selected wines. Food Chem 83:303–309

51.

Horn-Ross P, Barnes S, Lee M, Coward L, Mandel J, Koo J, John E, Smith M (2000) Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control 11:289–298PubMed

52.

Mazur W, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H (1998) Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 79:37–45PubMed

53.

Thompson LU, Robb P, Serraino M, Cheung F (1991) Mammalian lignan production from various foods. Nutr Cancer 16:43–52PubMedCrossRef

54.

Boucher B, Cotterchio M, Kreiger N, Nadalin V, Block T, Block G (2006) Validity and reliability of the Block98 food-frequency questionnaire in a sample of Canadian women. Public Health Nutr 9:84–93PubMed

55.

Holowaty E (2005) Cancer Care Ontario. Personal Communication

56.

Subar A, Thompson F, Kipnis V et al (2001) Comparative validation of the Block, Willett and National Cancer Institute food frequency questionnaires: the eating at America’s Table Study. Am J Epidemiol 154:1089–1099PubMed

57.

Gilbart E, Kreiger N (1998) Improvement in cumulative response rates following implementation of a financial incentive. Am J Epidemiol 148:97–99PubMed

58.

Mazur W (1998) Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 12:729–742PubMed

59.

Mazur W, Uehara M, Wahala K, Adlercreutz H (2000) Phyo-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J Nutr 83:381–387PubMed

60.

Meagher L, Beecher G (2000) Assessment of data on the lignan value of foods. J Food Compost Anal 13:935–947

61.

Lapcik O, Hill M, Hampl R, Wahala K, Adlercreutz H (1998) Identification of isoflavonoids in beer. Steroids 63:14–20PubMed

62.

Boker L, Van der Schouw Y, De Kleijn M, Jacques P, Grobbee D, Peeters P (2002) Intake of dietary phytoestrogens by Dutch women. J Nutr 132:1319–1328PubMed

63.

Horn-Ross P (2001) Assessing phytoestrogen exposure via a food-frequency questionnaire (letter). Cancer Causes Control 12:477–478PubMed

64.

Block G, Hartman A, Dresser C, Carroll M, Gannon J, Gardner L (1986) A data-based approach to diet questionnaire design and testing. Am J Epidemiol 124:453–469PubMed

65.

Block G (2001) Invited commentary: another perspective on food frequency questionnaires. Am J Epidemiol 154:1103–1104PubMed

66.

Hosmer D, Lemeshow S (2000) Applied logistic regression. John Wiley & Sons Inc., New York, NY

67.

Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138:923–936PubMed

68.

Colditz G, Atwood K, Emmons K et al (2000) Harvard report on cancer prevention, vol 4: Harvard cancer risk index. Cancer Causes Control 11:477–488PubMed

69.

Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health 79:340–349PubMedCrossRef

70.

Liggins J, Mulligan A, Runswick S, Bingham SA (2002) Daidzein and genistein content of cereals. Eur J Clin Nutr 56:961–966PubMed

71.

Mazur W, Fotsis T, Wahala K, Ojala S, Salakka A, Aldercreutz H (1996) Isotope dilution gas chromatographic-mass spectrometric method for the determination of isoflavonoids, coumestrol, and lignans in food samples. Anal Biochem 233:169–180PubMed

72.

Pillow P, Duphorne C, Chang S, Contois J, Strom S et al (1999) Development of a database for assessing dietary phytoestrogen intake. Nutr Cancer 33:3–19PubMed

73.

Silva dosSantos I, Mangtani P, McCormack V, Bhakta D, McMichael A, Sevak L (2004) Phytoestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case–control study. Cancer Causes Control 15:805–818

74.

McCann S, Kulkarni S, Trevisan M, Vito D, Nie J, Edge S, Muti P, Freudenheim J (2006) Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status. Breast Cancer Res Treat 99:309–311PubMed

75.

Bosetti C, Spertini L, Parpinel M, Gnagnarella P, Lagiou P et al (2005) LaVecchia C. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev 14:805–808PubMed

76.

Olsen A, Knudsen K, Thomsen B, Loft S, Stripp C, Overvad K, Moller S, Tjonneland A (2004) Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomarkers Prev 13:2084–2089PubMed

77.

Kilkkinen A, Virtamo J, Vartianen E, Sankila R, Adlercreutz H, Pietinen P (2004) Serum enterolactone concentration is not associated with breast cancer risk in a nested case–control study. Int J Cancer 108:277–280PubMed

78.

Hulten K, Winkvist A, Lenner P, Johansson R, Aldercreutz H, Hallmans G (2002) An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 4:168–176

79.

Dai Q, Franke A, Yu H, Shu X, Jin F, Hebert J, Custer L, Gao Y, Zheng W (2003) Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomarkers Prev 12:497–502PubMed

80.

Nelson L, Bulun S (2001) Estrogen production and action. J Am Acad Dermatol 45(3S):S116–S124PubMed

81.

Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-1 and IGF-binding protein-3;a cross sectional study in healthy women. Eur J Endocrinol 150:161–171PubMed

82.

Setchell K (1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutrition 68:1333S–1346S

83.

Han D, Tachibana H, Yamada K (2001) Inhibition of environmental estrogen-induced proliferation of human breast carcinoma MSF-7 cells by flavonoids. In Vitro Cell Dev Biol Anim 37:275–282PubMed

84.

Messina M, McCaskill-Stevens W, Lampe J (2006) Addressing the soy and breast cancer relationship: review, commentary and workshop proceedings. J Natl Cancer Inst 98:1275–1284PubMedCrossRef

85.

Shu X, Jin F, Dai Q et al (2001) Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 10:483–488PubMed

86.

Thanos J, Cotterchio M, Boucher B, Kreiger N, Thompson L (2006) Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 17:1253–1261PubMed

87.

Schedin P, Byers T (1997) Adolescent diet and the risk of breast cancer in adulthood: a role for vitamin A? Nutrition 13:924–925PubMed

88.

Lamartiniere C, Murrill W, Manzolillo P et al (1998) Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Exp Biol Med (Maywood) 217:358–364

89.

Tou J, Thompson L (1999) Exposure to flaxseed or its lignan component during different developmental stages influences rat mammary gland structures. Carcinogenesis 20:1831–1835PubMed

90.

Jin Z, MacDonald R (2002) Soy isoflavones increase latency of spontaneous mammary tumors in mice. J Nutr 132:3186–3190PubMed

91.

Krazeisen A, Breitling R, Moller G, Adamski J (2001) Phytoestrogens inhibit 17B-hydroxysteroid dehyrogenase type 5. Mol Cell Endocrinol 171:151–162PubMed

92.

Fotsis T, Pepper M, Aldercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Nat Acad Sci USA 90:2690–2694PubMed

93.

Dave B, Eason R, Till S, Geng Y, Velarde M, Badger T, Simmen R (2005) The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing the tumor suppressor PTEN. Carcinogenesis 26:1793–1803PubMed

94.

Anderson J, Anthony M, Messina M, Garner S (1999) Effects of phyto-oestrogens on tissues. Nutr Res Rev 12:75–116PubMed

95.

Strauss L, Santti R, Saarinen N, Streng T, Joshi S, Makela S (1998) Dietary phytoestrogens and their role in hormonally dependent disease. Toxicol Lett 102–102:349–354

96.

Barnes S, Boersma B, Patel R, Kirk M, Darley-Usmar V, Kim H, Xu J (2000) Isoflavonoids and chronic disease: mechanisms of action. BioFactors 12:209–215PubMed

97.

Haggans C, Hutchins A, Olson B et al (1999) Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 33:188–195PubMed

98.

Mueller S, Simon S, Chae K, Metzler M, Korach K (2004) Phytoestrogens and their human metabolites show distinct agonist and antagonist properties on ER-alpha and ER-beta in human cells. Toxicol Sci 80:14–25PubMed

99.

Enmark E, Gustafsson J (1999) Oestrogen receptors: an overview. J Inter Med 246:133–138

100.

Kuiper G, Lemmen J, Carlsson B, Corton J, Safe S, van der Saag P, van der Burg B, Gustafsson J (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139(10):4252–4263PubMed

101.

Petersson K, Delauunay F, Gustafsson JA (2000) Estrogen receptor beta acts as dominant regulator of estrogen signaling. Oncogene 19:4970–4978

102.

An J, Tzagarakis-Foster C, Scharschmidt T, Lomri N, Leitman D (2001) Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 21:17808–17814

103.

Kostelac D, Rechkemmer G, Briviba K (2003) Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem 26:7632–7635

104.

Kumar N, Cantor A, Allen K, Riccardi D, Cox C (2002) The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 94:1166–1174PubMed

105.

Xu X, Duncan A, Merz B, Kurzer M (1998) Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. Cancer Epidemiol Biomarkers Prev 7:1101–1108PubMed

106.

Martin M, Haourigui M, Pelissero C, Benassayag C, Nunez E (1996) Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 58:429–436PubMed

107.

Brooks JD, Thompson LU (2005) Mammalian lignans and genistein decrease the activities of aromatase and 17 beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Molec Biol 94:461–467PubMed

108.

Cassidy A (1996) Physiological effects of phyto-oestrogens in relation to cancer and other human health risks. Proc Nutr Soc 55:399–417PubMed

109.

Lu L, Cree M, Josyla S et al (2000) Increased urinary excretion of 2-hydroxyestrone but not 16-alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 60:1299–1305PubMed

110.

Lu L, Anderson K, Grady J, Kohen F, Nagamani M (2000) Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res 60:4112–4121PubMed

111.

Chen J, Stavro P, Thompson L (2002) Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43:187–192PubMed

112.

Kitts D, Yuan Y, Wijewickreme A, Thompson L (1999) Antioxidant activity of the flaxseed lignan SECO-diglycoside and its mammalian lignan metabolite enterodiol and enterolactone. Mol Cell Biochem 202:91–100PubMed

113.

Ruiz-Larrea M, Mohan A, Paganga G, Miller N, Bolwell G, Rice-Evans C (1997) Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 26:63–70PubMedCrossRef

114.

Su S, Yeh T, Chuang W, Ho C, Chang K et al (2005) The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 69:307–318PubMed

115.

Zhang S, Hunter D, Forman M, Rosner B, Speizer F, Colditz G, Manson J, Hankinson S, Willett W (1999) Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. JNCI 91:547–556PubMed

116.

Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A (2003) Bioavailability of phytoestrogens. Br J Nutr 89 (supp 1):S45–S58PubMed

117.

Atkinson C, Berman S, Humbert O, Lampe JW (2004) In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production. J Nutr 134:596–599PubMed

118.

Franke A, Custer L, Hundahl S (2004) Determinants for urinary and plasma isoflavones in humans after soy intake. Nutr Cancer 50:141–154PubMed

119.

Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Aldercreutz H (2002) Use of oral antibiotics decreases serum enterolactone concentration. Am J Epidemiol 155:472–477PubMed

120.

Atkinson C, Frankenfeld C, Lampe J (2005) Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Bio Med 203:155–170

121.

Greenwald P (2004) Clinical trials in cancer prevention:current results and perspectives for the future. J Nutr 134:3507S–3512SPubMed

Title: Dietary phytoestrogen intake—lignans and isoflavones—and breast cancer risk (Canada)
Authors: Michelle Cotterchio
Beatrice A. Boucher
Nancy Kreiger
Catherine A. Mills
Lilian U. Thompson
Publication date: 01-04-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 3/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-007-9089-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2008

Risk of childhood leukemia associated with parental smoking and alcohol consumption prior to conception and during pregnancy: the cross-Canada childhood leukemia study

Risk of thyroid cancer among Iranian immigrants in Sweden

The association between self-reported acrylamide intake and hemoglobin adducts as biomarkers of exposure

Analysis of lung cancer incidence in the nurses’ health and the health professionals’ follow-up studies using a multistage carcinogenesis model

UV radiation exposure, skin type and lymphoid malignancies: results of a French case–control study

Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S.

Keynote webinar | Spotlight on antibody–drug conjugates in cancer